Joint drugs controller nabbed taking bribe to clear Biocon unit's injection

The CBI registered a case of criminal conspiracy and corruption against Reddy, posted at CDSCO headquarters, and Dinesh Dua, Director at Synergy Network India Private Limited, among others.

vaccine, injection
Representative Image (Photo: Bloomberg)
Press Trust of India New Delhi
3 min read Last Updated : Jun 20 2022 | 10:58 PM IST

The CBI on Monday apprehended Joint Drugs Controller S Eswara Reddy for allegedly receiving a Rs 4-lakh bribe to waive phase-three clinical trial of Insulin Aspart injection, an underdevelopment product of Biocon Biologics, officials said.

After getting inputs about an exchange of bribe, the CBI registered a case of criminal conspiracy and corruption against Reddy, posted at CDSCO headquarters, and Dinesh Dua, Director at Synergy Network India Private Limited, among others.

The CBI, which was working on the input for over a month, carried out a raid and Dua was caught giving Rs 4-lakh bribe to Reddy of the total promised amount of Rs 9 lakh on behalf of Biocon Biologics, a subsidiary of Kiran Majumder Shaw-led Biocon, officials said.

"Phase 3 clinical trial is an important regulatory mechanism to assess the safety of a pharma product. Any attempt to waive them off can have serious public health safety repercussions," an official said.

The CBI has alleged that the regulatory work of Biocon Biologics was looked after by Guljit Sethi of Bioinnovat Research Services Private Ltd.

Bioinnovat and Synergy Network have business dealings hence Dua agreed to make the bribe payment, the probe agency has alleged.

The others named in the FIR include Guljit Sethi alias Guljit Chaudhary, Director, Bioinnovat Research Services Private Limited, Delhi; L Praveen Kumar, Associate Vice President and Head-National Regulatory Affairs (NRA), Biocon Biologics Limited, Bangalore; and Animesh Kumar, Assistant Drug Inspector (ADI), CDSCO, New Delhi.

Biocon spokesperson did not immediately reply to messages and phone calls made for comments.

The CBI has alleged that executives of Biocon Biologics were trying to exert undue influence on officers of Central Drugs Standard Control Organisation (CDSCO) under the Directorate General of Health Services, Ministry of Health and Family Welfare, to waive the phase 3 trial of 'Insulin Aspart Injection', officials said.

It was alleged that they agreed to pay a bribe of Rs 9 lakh to Reddy for "favourably processing" three files related to Biocon Biologics and also to favourably recommend the file of "Insulin Aspart injection" to the Subject Expert Committee (SEC) meeting, they said.

"The CBI laid a trap wherein the JDC of CDSCO was caught while accepting a bribe of Rs 4 lakh from the director of a Delhi-based private company. The said director was also caught," CBI spokesperson R C Joshi said.

The CBI conducted searches at 11 places in Delhi, Noida, Gurugram, Patna and Bengaluru which led to the recovery of incriminating documents and articles, he said.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :BioconCBIBribery

First Published: Jun 20 2022 | 10:58 PM IST

Next Story